Corestemchemon

At a glance

Corestemchemon filed 41 disclosures in the last 12 months, including 13 insider, 6 5% holder and 1 buyback. The most recent key filing was on Sep 3: President's holding fell by 1,585,072 sh (other change).

Revenue for 2025 was ₩20.2B, down 29.9% on 2024. It made an operating loss of ₩21.2B. Debt was 104% of equity at year end. The latest interim report (2026 H1) shows revenue of ₩9.7B and operating loss of ₩10.3B.

The 2025 annual report lists 321 employees with an average tenure of 6.1 years and average pay of ₩48.3M, #1815 of 2,191 listed companies by average pay. Its 8 directors and auditors were paid ₩63.9M each on average. It paid no cash dividend for 2025. 김경숙 and related parties held 9.74% at year end.

Of 3 recent 5%+ holder reports, 1 raised and 2 cut a stake; the largest stake reported was 14.24% on Dec 24.

From the 2025 annual report

Staff: 321 (141 men, 180 women), of whom 22 on fixed-term contracts. Total pay for the year: ₩15.4B. Directors and auditors: 8, paid ₩511.1M in total.

No cash dividend was paid for 2025.

Largest shareholder

김경숙 holds 6.49%; with 12 related parties the group holds 9.74% of common shares at year end (from 12.02% at the start of the year).

Auditor: 안진회계법인 · opinion: Unqualified.

Source: 2025 annual business report (DART). How figures are combined

Financial summary

5%+ holder reports